drugset / Trial / NCT03252171
CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.
Timeline
- Start
- 2015-10-15
- Primary completion
- 2016-08-15
- Completion
- 2016-08-15
Outcome
Outcome not reported
Stopped: “Project terminated due to revision of local regulations”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-T cell immunotherapy | Cell therapy | — | Other |